https://www.ambergen.com/wp-content/uploads/logo-retina.png 0 0 Kenneth Rothschild https://www.ambergen.com/wp-content/uploads/logo-retina.png Kenneth Rothschild2018-01-25 07:37:572018-04-25 07:47:37AmberGen awarded $2 million, 2-year Phase IIb SBIR grant from NIH-NIAID to further develop its PC-PURE™-assisted, multiplex, in vitro AllerBead™ assay which uses finger-stick blood for the highly multiplex quantification of allergen-specific IgE
Get in Touch
313 Pleasant St.
Watertown, MA 02472
- AmberGen receives US Patent 9,910,034 increasing its broad coverage on PC-PURE™ photo-affinity biomarker purification and enrichment technology for improving the accuracy of diagnostic testing March 2018
- Paper published in PLOS ONE in collaboration with Boston Children’s Hospital “Photocleavage-based affinity purification of biomarkers from serum: Application to multiplex allergy testing” describing application of AmberGen’s PC-PURE™ to highly multiplex in vitro allergy testing (AllerBead™) February 2018